Morbidity and Mortality after General Surgery in Heart and Lung Transplant Patients

2019 ◽  
Author(s):  
Alek Zywot ◽  
Amber L. Turner ◽  
Joanna Sesti ◽  
Russell C. Langan ◽  
Andrew Nguyen ◽  
...  
Keyword(s):  
General Surgery ◽  
Lung Transplant ◽  
Morbidity And Mortality ◽  
Transplant Patients

scholarly journals Morbidity and mortality after general surgery in heart and lung transplant patients

2020 ◽  
Vol 2 (3) ◽  
pp. 140-146
Author(s):  
Alek Zywot ◽  
Amber L. Turner ◽  
Joanna Sesti ◽  
Russell C. Langan ◽  
Andrew Nguyen ◽  
...  
Keyword(s):  
General Surgery ◽  
Lung Transplant ◽  
Morbidity And Mortality ◽  
Transplant Patients

scholarly journals Twelve-month effects of everolimus on renal and lung function in lung transplantation: differences in chronic lung allograft dysfunction phenotypes

2021 ◽  
Vol 12 ◽  
pp. 204062232199344
Author(s):  
Filippo Patrucco ◽  
Elias Allara ◽  
Massimo Boffini ◽  
Mauro Rinaldi ◽  
Cristina Costa ◽  
...  
Keyword(s):  
Renal Function ◽  
Lung Function ◽  
Lung Transplant ◽  
Bronchiolitis Obliterans Syndrome ◽  
Forced Expiratory Volume ◽  
Chronic Lung Allograft Dysfunction ◽  
Allograft Dysfunction ◽  
Transplant Patients ◽  
Restrictive Allograft Syndrome ◽  
Trend Data

Background: Chronic lung allograft dysfunction (CLAD), a complication affecting the survival of lung transplanted patients, includes two clinical phenotypes: bronchiolitis obliterans syndrome (BOS) and restrictive allograft syndrome (RAS). Everolimus is used in CLAD because of its antiproliferative mechanism. In lung transplant patients treated with everolimus, the clinical course of renal and lung function has not yet been assessed systematically in CLAD, BOS and RAS patients for more than 6 months. Methods: We retrospectively evaluated the 12-month follow-up of renal and lung function of lung-transplanted patients switched to everolimus and evaluated the reduction in immunosuppressant dosage (ISD) and mortality. Subgroups were based on indication for everolimus treatment: CLAD and non-CLAD patients, BOS and RAS among CLAD patients. Results: We included 26 patients, 17 with CLAD (10 BOS, seven RAS). After 1 year from the everolimus switch, we observed renal function improvement (serum creatinine −17%, estimated glomerular filtration rate +24%) and stable pulmonary function [forced expiratory volume in the first second (FEV1) −0.5%, forced vital capacity (FVC) +0.05%]. RAS patients had progressive functional loss, whereas BOS patients had FEV1 improvement and FVC stability. All-cause mortality was higher in the CLAD versus non-CLAD group (41% versus 11%), without differences between BOS and RAS patients ( p > 0.05). All patients had significant and persistent ISD reduction. Conclusion: Lung transplant patients treated with everolimus had improvements in renal function and reduced ISD. We observed sustained improvements in lung function for CLAD related to BOS subgroup results, whereas RAS confirmed the 1-year worsening functional trend. Data seem to suggest one more piece of the puzzle in CLAD phenotyping.

Comparison of Leukolysin/MT6-MMP in Bronchoalveolar Lavage Fluid from Lung Transplant Patients and Asthmatics

2006 ◽  
Vol 117 (2) ◽  
pp. S64
Author(s):  
J.P. Raasch ◽  
C.L. Liebeler ◽  
C.H. Wendt ◽  
J.B. Sweet ◽  
N.N. Jarjour ◽  
...  
Keyword(s):  
Bronchoalveolar Lavage ◽  
Lung Transplant ◽  
Bronchoalveolar Lavage Fluid ◽  
Lavage Fluid ◽  
Transplant Patients

Neuromuscular Painful Disorders: a Rare Side Effect of Voriconazole in Lung Transplant Patients Under Tacrolimus

2008 ◽  
Vol 27 (2) ◽  
pp. 229-232 ◽  
Author(s):  
V. Boussaud ◽  
N. Daudet ◽  
E.M. Billaud ◽  
A. Lillo-Le Louet ◽  
P. Chevalier ◽  
...  
Keyword(s):  
Side Effect ◽  
Lung Transplant ◽  
Transplant Patients ◽  
Rare Side Effect
Sign in / Sign up

Export Citation Format

Share Document